Mersana Therapeutics (MRSN) News and press releases

Mersana Therapeutics's Return On Capital Employed Insights

24 May 23

Earnings

Citigroup Maintains Buy on Mersana Therapeutics, Raises Price Target to $15

11 May 23

News, Price Target, Analyst Ratings

Citigroup analyst Ashik Kurian maintains Mersana Therapeutics (NASDAQ:MRSN) with a Buy and raises the price target from $12 to $15.

Mersana Therapeutics Q1 EPS $(0.52) Misses $(0.44) Estimate, Sales $7.80M Miss $18.29M Estimate

9 May 23

Earnings, News

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.44) by 18.18 percent. This is a 11.86 percent increase over losses of $(0.59) per share

Earnings Scheduled For May 9, 2023

9 May 23

Earnings

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.

12 Health Care Stocks Moving In Wednesday's Intraday Session

3 May 23

Movers

US Stocks Edge Higher; AMD Shares Tank Despite Upbeat Results

3 May 23

Earnings, News, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas

U.S. stocks traded up this morning, ahead of the Federal Reserve’s decision on an interest rate hike. Following the market opening Wednesday, the Dow traded up 0.05% to 33,700.93 while the NASDAQ rose 0.17% to 12,100.98. The S&P 500 also gained 0.17% to 4126.77.

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023

16 Mar 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

JP Morgan Upgrades Mersana Therapeutics to Overweight, Announces $10 Price Target

16 Mar 23

News, Upgrades, Price Target, Analyst Ratings

JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Overweight and announces $10 price target.

FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death

13 Mar 23

Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, Movers, Trading Ideas, General

The FDA has placed a clinical hold on Mersana Therapeutics' Phase 1 trial of XMT-2056

13 Mar 23

Biotech, News, Health Care, FDA, General

The move follows the voluntary suspension of the trial due to a recent Grade 5 (fatal) serious adverse event (SAE) that was deemed to be related to XMT-2056. The SAE and its cause remain under investigation.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 Jun 23

Markets, Press Releases

CAMBRIDGE, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

Mersana Therapeutics to Present at Upcoming Investor Conferences

24 May 23

News, Press Releases

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 May 23

Press Releases

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

Thinking about buying stock in ImmunoGen, Mersana Therapeutics, Unisys, Eyepoint Pharmaceuticals, or BioCryst Pharmaceuticals?

3 May 23

Opinion, Press Releases

NEW YORK, May 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMGN, MRSN, UIS, EYPT, and BCRX.

Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023

2 May 23

News, Press Releases

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

26 Apr 23

News, Press Releases

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 Apr 23

Press Releases

CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

13 Mar 23

Health Care, Press Releases

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

Mersana Therapeutics Provides Statement About SVB

10 Mar 23

Press Releases

CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates